Global Health Partnerships

Partnership Objectives

  1. To support promising public health models though programmatic grants and ongoing technical assistance.
  2. To develop a culture of results-oriented discovery and innovation by providing customized technical assistance in monitoring and evaluation.
  3. To advance the field by providing opportunities for GHP partners to share promising models and lessons learned with one another and at major conferences.
  4. To foster strong peer learning and potential global collaborations between the GHP organizations through regular in-person and virtual meetings.

Partnerships that demonstrate measurable impact in tobacco control and cancer control. Partnerships that demonstrate measurable impact in tobacco control and cancer control. Copyright Pfizer

Description of the health needs

Cancer is one of the most pressing health challenges of our time.

By 2020, the incidence of new cancers is expected to rise by 50 percent to between 15 million cases and 16 million cases annually. Of these, 75 percent will strike in developing countries, those least prepared to respond. Yet, 40 percent of all cancer deaths can be prevented; tobacco use is the largest single preventable cause of cancer.

Description of partnership activities and how they address needs and challenges

Pfizer is combating the global cancer epidemic by investing in the growth of promising cancer- and tobacco-control organizations around the world and bringing them together to form a global peer network through the Global Health Partnerships program. One of the most powerful elements of this program lies in the unification of 31 non-governmental organizations (NGOs) from around the world around a single mission: to accelerate the pace of progress in the fight against cancer. GHP grantees supported cancer and tobacco control in seven programmatic focus areas:

  • Building the evidence for enhancing care;
  • Screening to save lives;
  • Navigating patients through complicated systems of care;
  • Building awareness about the harm of tobacco use;
  • Developing tobacco control capacity;
  • Protecting nonsmokers from secondhand smoke; and
  • Helping smokers quit.

The Global Health Partnerships program combined the global philanthropic and in-kind resources of the Pfizer Foundation and Pfizer Inc. Together, the Foundation and local Pfizer offices around the world are comitted USD 47 million over four years (2008-2011) in promising cancer- and tobacco-control projects with programmatic grants, targeted technical assistance, and peer learning and networking opportunities.

The Pfizer Foundation supported the GHP in several fundamental ways:

  • Tailored technical assistance from Johns Hopkins University to support successful program implementation and to build evaluation capacity
  • Individualized planning sessions
  • Training workshops
  • Webinars to build skills
  • Evaluation tools / manuals
  • Sponsorship of leading international conferences to gain cutting-edge knowledge and exposure to global experts
  • World Cancer Congress (Switzerland and China)
  • Global Health Alliance (Greece)
  • GHP Evaluation Workshop (La Jolla, CA)
  • World Tobacco Control Conference (India)
  • Network building to foster global community of practitioners in the fight against cancer
  • Peer-to-Peer online networking and information sharing
  • Easy access to best practice data
  • Linking organizations in country, regionally and internationally

Lessons learned

  • Customized Messaging & Outreach: Necessary in order to go beyond general public awareness, reach underserved communities and to reflect genuine cultural competency.
  • Identifying a Community “Champion”: To impact systemic challenges such as stigma, a selected cancer advocate, political figure, or private sector leader can raise awareness and sustain the community change beyond the grant period.
  • Investment in Evaluation: Despite some initial resistance, NGOs noted positive lessons including more effective communications with funders and policy makers and the ability to make more data-driven program decisions.
  • Aligning Grants with Technical Assistance: The complementary implementation of on-the-ground consulting, evaluation support, and organizational capacity building furthered the impact of grant funding on program outcomes.

Partnership information

Company(ies) Pfizer

Partner(s) Action on Smoking and Health (ASH), Akebono-Kai Breast Cancer Network, Alianca de Controle do Tabagismo, American Cancer Society, Bloomberg School of Public Health, Johns Hopkins University, Cancer Foundation of China, Cancer Institute, George Washington University, Cause Marketing Fundraisers of South Africa, Chinese Association on Tobacco Control, Comprehensive Cancer Center, European Organisation for Research and Treatment of Cancer (EORTC), Framework Convention Alliance, Good Dog Foundation, Healh Policy Institute Japan, Health Promotional Foundation Poland, Heart and Stroke Foundation of Ontario, Hellenic Thoracic Society, Hungarian Academy of Teaching Family Physicians, International Union Against Cancer, Irish Cancer Society, Japan Medical-Dental Association for Tobacco Control, Mexican Council Against Tobacco, Partnership for Prevention, Philippine Business for Social Progress, QUIT UK & European Network of Quitlines, Ralph Lauren Center for Cancer Care and Prevention, SAMBA Sweden, Shanghai Center for Disease Control and Prevention, SUVAK: New Hope in Health Foundation, Umberto Veronesi Foundation, Union for International Cancer Control (UICC)

Type of Partner(s) Academia / Hospitals, Multilaterals, NGOs, Professional Associations

Therapeutic Focus Non-Communicable Diseases

Disease(s) Breast Cancer, Cancer, Cervical Cancer, Tobacco Control

Program Type(s) Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Targeted Population(s) General population, Men, People with low income, Women, Youth

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, North America, Sub-Saharan Africa

Number of Countries 23

Country(ies) Algeria, Argentina, Brazil, Bulgaria, Chile, China, Colombia, Costa Rica, Czech Republic, Egypt, Estonia, Hungary, Japan, Jordan, Kenya, Latvia, Slovakia, South Africa, Thailand, Tunisia, Turkey, United States of America, Venezuela

Start Date 2006

More information Pfizer Responsibility

Completed date 2011